Covid-19 Update — House of Commons, 2021-05-17
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): Let me address the hon. Gentleman’s substantive questions. The first was about the surging of vaccines and testing into hotspots. We saw in south London earlier in the month and last month that that sort of surge testing can work. We had an outbreak of the South African variant in south London. We put in more than 200,000 tests, and we effectively managed to contain that outbreak. That is the approach that we are taking in Bolton and Blackburn, and we will also take that approach if we see a further spread in other areas of the country. We have been working very hard on that to ensure we have that capacity and can do that effectively. We do that, of course, hand in glove with the local authorities in question, which know the communities on the ground We are also making sure we have the vaccines available, but I want to be absolutely crystal clear about the approach to vaccination. The hon. Gentleman asked about vaccinating all over-18s in Bolton and Blackburn, but that is not our approach. I have looked into it in great detail, and we have taken clinical advice. The approach is to make sure that we get done as many second vaccinations as possible, as many first vaccinations as possible among the vulnerable groups, and then as many vaccinations as possible among those aged under 50 in the eligible groups. We have taken that approach because that is what is likely to save most lives. That second jab is vital. The first jab for anybody over 50 could mean the difference between life and death. The very strong focus is to get the vaccine to all those over 50 who have not yet taken the first jab. I am glad to say that reports from both Bolton and Blackburn suggest that uptake among people who are eligible, but who have not yet taken the jab, has increased since we saw the rise of the B1617.2 variant in those areas. It is effective in proving to people that the jab really does work to protect them. That is what the data shows The hon. Gentleman asked about children. I have been closely following the results of the clinical studies from Pfizer that show that the vaccine is safe and effective among children between the ages of 12 and 18. We have procured enough Pfizer to be able to offer that jab to children should that be clinically approved here, but given that we are at the stage of opening tomorrow to people aged 37, there is some time to go before we get to 18-year-olds. We are on track to meet the target of offering the vaccine to all those aged 18 and above by the end of July, so we have a couple of months before we need to make and operationalise a decision. We want to be very, very careful and sensitive about whether and how we offer the vaccine to children The hon. Gentleman asked about important wider measures. He mentioned ventilation. We have put in place guidance for businesses in terms of strengthening the rules around ventilation, and that, too, is important. He did a bit of a Captain Hindsight act on the Indian variant. He did not seem to mention that we put India on the red list before this variant was even deemed a variant under investigation, let alone a variant of concern. Indeed, we put India on the red list before countries such as Germany and Canada stopped flights from India. We have a strong policy of restrictions at the border and we will remain vigilant The final point to which I wanted to respond was on the global moral responsibility to vaccinate everybody in the world. The hon. Gentleman is absolutely right that we have a global moral responsibility. I argue that, thus far, the United Kingdom has done, and will continue to do, more than any other nation. It is about not just the huge sums that we have put into COVAX, but the way that we delivered the Oxford-AstraZeneca vaccine around the world. As of this morning, 1.47 billion vaccines have been delivered globally, 400 million of which have been the Oxford-AstraZeneca vaccine. AstraZeneca has charged a profit margin and a margin for intellectual property of zero—no charge for intellectual property, no profit for AstraZeneca. Costs, of course, need to be met, but we have taken nothing for the money that we put into the vaccine’s development. This is the biggest gift that this country could give to the world. A total of 65% of those 400 million doses have been delivered into the arms of people in low and middle-income countries, including more than 150 million in India. On the COVAX facility, which is the biggest global effort to vaccinate in low and middle-income countries, it has delivered 54 million vaccines so far, 53 million of which have been done with the Oxford-AstraZeneca vaccine This country can be hugely proud of the contribution it has made. It is far bigger so far than that of any other country. We took the view from the start that we do not need to change our IP rules, we do not need to change the law, we just need to get on and get the vaccine out to as many people around the world as possible, at cost. Everybody in this House should be very, very proud of what AstraZeneca and Oxford University have done with the support of the UK Government. That is how we save lives around the world.